1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Interaction between Nalbuphine and Alfentanil on Intraocular Pressure and Pupil Size of Conscious Rabbits

      ,

      Ophthalmic Research

      S. Karger AG

      Alfentanil, Intraocular pressure, Pupil size, Nalbuphine

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The ocular hypertension caused by the μ agonist alfentanil (10 μg/kg, i.v.) in spontaneously breathing rabbits was reversed to ocular hypotension by pretreatment with the k agonist-μ antagonist, nalbuphine (0.6 mg/kg, i.v.). This is probably due to nalbuphine’s μ antagonistic action which prevents the respiratory-depressant effect of alfentanil that elevates the blood pCO<sub>2</sub> with a drop in blood pH. It is known that hypoxia and hypercarbia lead to uveal vasodilation and increase in aqueous production which cause elevation of intraocular pressure. Both alfentanil and nalbuphine have miotic effects when used individually. However, no further reduction in the pupil size was noted by their combined use. These results indicate that using nalbuphine and alfentanil together may be considered a safe combination for eye surgery because it preserves the analgesic effect of either drug while prevents the undesirable respiratory-center depression and the ocular hypertension observed with alfentanil alone.

          Related collections

          Author and article information

          Journal
          ORE
          Ophthalmic Res
          10.1159/issn.0030-3747
          Ophthalmic Research
          S. Karger AG
          0030-3747
          1423-0259
          1989
          1989
          10 December 2009
          : 21
          : 2
          : 134-140
          Affiliations
          Institute of Ocular Pharmacology, Department of Medical Pharmacology and Toxicology, Texas A&M University College of Medicine, College Station, Tex., USA
          Article
          266791 Ophthalmic Res 1989;21:134–140
          10.1159/000266791
          2499854
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Comments

          Comment on this article